Trimethyl chitosan-hyaluronic acid nano-polyplexes for intravitreal VEGFR-2 siRNA delivery: Formulation and in vivo efficacy evaluation
- 10 March 2020
- journal article
- research article
- Published by Elsevier BV in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 26, 102181
- https://doi.org/10.1016/j.nano.2020.102181
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challengesAdvanced Drug Delivery Reviews, 2018
- Gene delivery nanoparticles to modulate angiogenesisAdvanced Drug Delivery Reviews, 2016
- Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal NeovascularizationMolecular Pharmaceutics, 2016
- Targeting VEGF in eye neovascularization: What's new?Pharmacological Research, 2015
- Treatment of ocular disorders by gene therapyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
- Encapsulated cells for long-term secretion of soluble VEGF receptor 1: Material optimization and simulation of ocular drug responseEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
- Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.Current Drug Targets, 2011
- Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eyeJournal of Controlled Release, 2010
- Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNAAdvanced Drug Delivery Reviews, 2006
- The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditionsClinical Science, 2005